Treatment of dyslipidaemias in patients with established vascular disease: A revival of the fibrates

Current Medical Research and Opinion

Volumn 16, Issue 1, 2000, Pages 21-32

  Milionis, Haralampos J ^a   Elisaf, Moses S ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cholesterol; Ciprofibrate; Dyslipidaemia; Fibrates; Fibrinogen; High density lipoprotein; Ischaemic heart disease; Lipoprotein (a); Low density lipoprotein; Low density lipoprotein subfractions; Triglyceride

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; CLOPIDOGREL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 0033951833     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079900542786     Document Type: Review

References (89)

1. The Lipid Research Clinic's Coronary Primary Prevention Trial results (1984). II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J. Am. Med. Assoc., 251, 365-374.
2. West of Scotland Coronary Prevention Group (1996). West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet, 348, 1339-1342.
3. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H. and Packard, C. J. for the West of Scotland Coronary Prevention Study Group (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med., 333, 1301-1307.
4. Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet, 344, 1383-1389.
5. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C. C., Davis, B. R. and Braunwald, E. for the Cholesterol and Recurrent Events Trial Investigators (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001-1009.
6. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349-1357.
7. Assmann, G. and Shulte, H. (1992). Relation of high density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am. J. Cardiol., 70, 733-737.
8. de Backer, G., de Bacquer, D. and Kornitzer, M. (1998). Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis, 137 (Suppl), SI-S6.
9. Hokanson, J. E. and Austin, M. A. (1996). Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective-studies. J. Cardiovasc. Risk, 3, 213-219.
10. Jeppensen, J., Hein, H. O., Susdicani, P. and Gyntelberg, F. (1997). Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow up in the Copenhagen Male Study. Arterioscl. Thromb. Vasc. Biol., 17, 1114-1120.
11. Dahlen, G. H. (1994). Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis, 108, 111-126.
12. Cremer, P., Nagel, D., Labrot, B., Mann, H., Muche, R., Elster, H. and Seidel, D. (1994). Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen - LDL cholesterol and other risk factors - results from the prospective Göttingen Risk Incidence and Prevalence study (GRIPS). Eur. J. Clin. Invest., 24, 444-453.
13. Mikhailidis, D. P., Ganotakis, E. S., Jagroop, I. A. and Winder, A. F. (1996). Beneficial effects of statins. Lancet, 348, 1079-1082.
14. Heinrich, J., Ballesen, L., Schulte, H., Assmann, G. and van der Loo, J. (1994). Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler. Thromb., 14, 54-59. Correction: Arterioscler. Thromb. 14, 1392 (1994).
15. Thompson, S. G., Kienast, J., Pyke, S. D. M., Haverkate, G. and van der Loo, J. C. (1995). Haemostatic and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med., 332, 635-641.
16. Ernst, E. and Resch, K. L. (1993). Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med., 118, 956-963.
17. Brown, G., Albers, J. J., Fisher, L. D., Shaefer, S. M., Lin, J. T., Kaplan, C., Zhao, X. Q., Bisson, B. D., Fitzpatrick, V. F. and Dodge, H. T. (1990). Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med., 323, 1289-1298.
18. Heiberg, A. G. and Slack, J. (1977). Family similarities in the age at coronary death in familial hypercholesterolaemia. Br. Med. J., 2, 493-495.
19. Anderson, K. M., Castelli, W. P. and Levy, D. (1987). Cholesterol and mortality. 30 years of follow-up from the Framingham Study. J. Am. Med. Assoc., 257, 2176-2180.
20. Assmann, G., Cullen, P. and Shulte, H. (1998), the Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur. Heart. J., 19 (Suppl A), A2-A11.
21. Koenig, W. (1995). Recent progress in the clinical aspects of fibrinogen. Eur. Heart. J., 16 (Suppl A), 54-59.
22. Breimer, L. H., Ganotakis, E. S. and Mikhailidis, D. P. (1997). Fibrinogen as a cardiovascular risk factor. Rev. Port. Cardiol., 16, 245-250.
23. Austin, M. A., Breslow, J. L., Hennekens, C. H., Buring, J. E., Willet, W. C., Krauss, R. M. (1988). Low density lipoprotein subclass patterns and risk of myocardial infarction. J. Am. Med. Assoc., 260, 1917-1925.
24. O'Brien, R. (1994). Biological importance of low density lipoprotein subfractions. J. Cardiovasc. Risk, 1, 207-211.
25. Krauss, R. M. (1994). Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr. Opin. Lipidol., 5, 339-349.
26. Chapman, M. J., Guerin, M. and Bruckert, K. (1998). Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur. Heart J., 19 (Suppl A), A24-A30.
27. Bruckert, E., Dejager, S. and Chapman, M. J. (1993). Ciprofibrate therapy normalizes the atherogenic low density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis, 100, 91-102.
28. Gaw, A., Packard, C. J., Caslake, M., Griffin, B. A., Lindsay, G. M., Thompson, J., Vallance, B. D., Wosornu, D. and Shepherd, J. (1994). Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis, 108, 137-148.
29. Sattar, N., Petrie, J. R. and Jaap, A. J. (1998). The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis, 138, 229-235.
30. Krauss, R. M. (1998). Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. 81 (4A), 13B-17B.
31. Lewis, G. F. and Steiner, G. (1996). Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care, 19, 390-393.
32. Yoshino, G., Hirano, T. and Kazumi, T. (1996). Dyslipidaemia in diabetes mellitus. Diabetes Res. Clin. Prac., 33, 1-14.
33. Criqui, M. H., Heiss, G., Cohn, R., Cowan, L. D., Suchindran, C. M., Bangdiwala, S., Kritchevsky, S., Jacobs, D. R. Jr, O'Grady, H. K. and Davis, C. E. (1993). Plasma triglyceride level and mortality from coronary heart disease. N. Engl. J. Med., 328, 1220-1225.
34. Durrington, P. N. (1998). Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis, 141 (Suppl), S57-S62.
35. Laakso, M., Lehto, S., Penttila, I. and Pyorala, K. (1993). Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin dependent diabetes. Circulation, 88, 1421-1430.
36. West, K. M., Ahuja, M. M. S., Bennett, P. H., Czyzyk, A., De Acosta, O. M., Fuller, J. H., Grab, B., Jarrett, R. S., Kosaka, K. et al. (1983). The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care, 6, 361-369.
37. Fontbonne, A., Eschwege, E., Cambien, F., Richard, J. L., Ducimetiere, P., Thibult, N., Warndet, J. M., Claude, R. and Rosselin, G. E. (1989). Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes; results from the 11-year follow-up of the Paris Prospective Study. Diabetologia, 32, 300-304.
38. James, R. W. and Pometta, D. (1990). Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects. Diabetes, 39, 1158-1164.
39. James, R. W. and Pometta, D. (1991). The distribution profiles of very low density and low density lipoproteins in poorly controlled male, type 2 (non-insulin dependent) diabetic patients. Diabetologia, 34, 246-252.
40. Simpson, H. C., Williamson, C. M., Olivecrona, T., Pringle, S., Maclean, J., Lorimer, A. R., Bonnefous, F., Bogaievsky, Y., Packard, C. J. and Shepherd, J. (1990). Postprandial lipaemia, fenofibrate and coronary artery disease. Atherosclerosis, 85, 193-202.
41. Assmann, G. and Schulte, H. (1992). Relation of high-density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am. J. Cardiol., 70, 733-737.
42. Petersen, T. R., Olsson, A. G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyorala, K., Miettinen, T., Christophersen, B., Tobert, J. A., Musliner, T. A. and Cook, T. J. for the Scandinavian Simvastatin Survival Study Group (1998). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97, 1453-1460.
43. de Backer, G. (1984). Nutrition and health. An interuniversity study. Regional differences in dietary habits, coronary risk factors and mortality rates in Belgium. Acta Cardiol., XXXIX, 285-292.
44. Maggi, F. M., Poglionica, M. R., De Michele, L., Baroni, S., Biasi, G. M. and Catapano, A. L. (1994). Bezafibrate lowers elevated plasma levels of fibrinogen and lipoprotein (a) in patients with type IIa and b dyslypoproteinaemia. Nutr. Metab. Cardiovasc. Dis., 4, 215-220.
45. Perez-Jimenez, J. A., Hidalgo, L., Zambrana, J. L., Artizon, J. M., Jimenez-Pereperez, J. A., Concha, M., Espino, A., Blanco, J., Valles, F. and Lopez-Miranda, J. (1995). Comparison of lovastatin and bezafibrate on lipoprotein (a) plasma levels in cardiac transplant recipients. Am. J. Cardiol., 75, 648-650.
46. Mikhailidis, D. P., Ganotakis, E. S., Spyropoulos, K. A., Jagroop, I. A., Byrne, D. J. and Winder, A. F. (1998). Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate of lifestyle advice. Int. Angiol., 17, 225-233.
47. Koenig, W., Hehr, R., Ditschuneit, H. H., Kuhn, K., Ernst, E., Rosenthal, J. and Hombach, V. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein (a). J. Clin. Pharmacol., 32, 539-545.
48. Kostner, G. M., Gavish, D., Leopold, B., Bolzano, K., Weintraub, M. S. and Breslow, J. L. (1989). HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation, 80, 1313-1319.
49. Slunga, L., Johnson, O. and Dahlen, G. H. (1992). Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolemia with simvastatin. Eur. J. Clin. Pharmacol., 43, 369-373.
50. Hunninghake, D. B., Stein, E. A. and Mellies, M. J. (1993). Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein (a). J. Clin. Pharmacol., 33, 574-580.
51. Mikhailidis, D. P. and Winder, A. F. (1995). A place for fibrinogen-lowering drugs in cardiovascular disease? J. Drug Develop. Clin. Pract., 7, 61-70.
52. Stringer, M. D., Steadman, C. A. and Kakkar, V. V. (1990). Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease. Curr. Med. Res. Opin., 12, 207-214.
53. Branchi, A., Rovellini, A., Sommariva, D., Gugliandolo, A. G. and Fasoli, A. (1993). Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolaemia. Thromb. Haemost., 70, 241-243.
54. Wilkes, H. C., Meade, T. W., Barzegar, S., Foley, A. J., Hughes, L. O., Bauer, K. A., Rosenberg, R. D. and Miller, G. J. (1992). Gemfibrozil reduces plasma prothrombin fragment F 1+2 concentration, a marker of coagulability in patients with coronary heart disease. Thromb. Haemost., 67, 503-506.
55. Wierzbicki, A. S., Lumb, P. J., Semra, Y. K. and Crook, M. A. (1998). Effect of atorvastatin on plasma fibrinogen. Lancet, 351, 569-570.
56. Nair, D. R., Papadakis, J. A., Jagroop, I. A., Mikhailidis, D. P. and Winder, A. F. (1998). Statins and fibrinogen. Lancet, 351, 1430.
57. Bertolotto, A., Bandinelli, S., Ruocco, L., Lo Faro, A., Penno, G. and Navalesi, R. (1999). More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. Atherosclerosis, 143, 455-457.
58. Jones, P. H., Pownall, H. J., Patsch, W., Herd, J. A., Farmer, J. A., Payton-Ross, C., Kimball, K. T., Gotto, A. M. and Morrisett, J. D. (1996). Effect of gemfibrozil on levels of lipoprotein (a) in type II hyperlipoproteinemic subjects. J. Lipid Res., 37, 1298-1308.
59. Bredie, S. J., Westerveld, H. T., Knipscheer, H. C., de Bruin, T. W., Kastelein, J. J., Stalenhoef, A. F. (1996). Effects of gemfibrozil or simvastatin on apolipoprotein-B containing lipoproteins, apolipoprotein-CIII and lipoprotein (a) in familial combined hyperlipidemia. Netherlands J. Med., 49, 59-67.
60. Ramires, J. A., Sposito, A. C., Mansur, A. P., Solimene, M. C., Chamone, D., da Luz, P. L. and Pileggi, F. (1997). Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients. Arq. Brasil Cardiol., 68, 257-260.
61. Ericsson, C.-G., Hamsten, A., Nilsson, J., Grip, L., Svane, B. and Defaire, U. (1996). Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet, 347, 849-853.
62. MAAS Investigators (1994). Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet, 344, 633-638.
63. Jukema, I. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H., Bal, E. T., Zwinderman, A. H. et al. on behalf of REGRESS Study Group (1995). Effects of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation, 91, 2528-2540.
64. Carlson, L. A. and Rosenhamer, G. (1988). Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand., 223, 405-418.
65. Frick, M. H., Syvanne, M., Nieminen, M. S. et al. for the Lopid Coronary Angiography Trial (LOCAT) Study Group (1997). Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation, 96, 2137-2143.
66. Behar, S. for the BIP Study Group (1999). Lowering fibrinogen levels: clinical update. Blood Coagul. Fibrinol., 10 (Suppl 1), S41-S43.
67. Rubins, H. B., Robins, S. J., Collins, D. et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med.; 341, 410-418.
68. Betteridge, D. J. and O'Bryan-Tear, C. G. (1996). Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. Postgrad. Med. J., 72, 739-743.
69. Bruckert, E., Gheron, G. and Dairou, F. (1994). Comparisons of the efficacy and tolerance of ciprofibrate and gemfibrozil in the treatment of type IIa and IIb hyperlipidaemia. Synthese Med., 429, 14-16.
70. Feussner, G., Kurth, B. and Lohrmann, J. (1997). Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia. Eur. J. Med. Res., 2, 165-168.
71. Zimetbaum, P., Frishman, W. H. and Kahn, S. (1991). Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J. Clin. Pharmacol., 31, 25-37.
72. Knipscheer, H. C., de Valois, J. C., van den Ende, B., ten Cate, J. W. and Kastelein, J. J. P. (1996). Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia. Atherosclerosis, 124 (Suppl), S75-S81.
73. East, C., Bilheimer, D. W. and Grundy, S. M. (1988). Combination drug therapy for familial combined hyperlipidemia. Ann. Intern. Med., 109, 25-32.
74. Papadakis, J. A., Ganotakis, E. S., Jagroop, I. A., Winder, A. F. and Mikhailidis, D. P. (1999). Statin + fibrate combination therapy. Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int. J. Cardiol., 69, 237-244.
75. Ganotakis, E. S. and Mikhailidis, D. P. (1996). Bezafibrate: treating hyperlipidemias as well as other cardiovascular risk factors. Today's Therap. Trends, 13, 231-249.
76. Horsmans, Y., Desager, J. P. and Harvengt, C. (1992). Effects of combined bezafibrate-simvastatin appraised in healthy subjects. J. Clin. Pharmacol., 32, 422-426.
77. Feher, M. D., Foxton, J., Banks, D., Lant, A. F. and Wray, R. (1995). Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br. Heart J., 74, 14-17.
78. Shepherd, J. (1995). Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur. Heart J., 16, 5-13.
79. Stein, E. A., Lane, M. and Laskarzewski, P. (1998). Comparison of statins in hypertriglyceridemia. Am. J. Cardiol., 81(4A), 66B-69B.
80. Levenson, J., Giral, P., Megnien, J. L., Gariepy, J., Plainfosse, M. C. and Simon, A. (1997). Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hypercholesterolemic men. Arterioscler. Thromb. Vasc. Biol., 17, 45-50.
81. Papadakis, J. A., Mikhailidis, D. P. and Winder, A. F. (1998). Lipids and stroke: neglect of a useful preventive measure? Cardiovasc. Res., 40, 265-271.
82. Papadakis, J. A., Ganotakis, E. S., Jagroop, I. A., Mikhailidis, D. P. and Winder A. F. (1999). Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am. J. Hypertens, (in press).
83. Antiplatelet Trialists' Collaboration (1994). Collaborative overview on randomised trials of antiplatelet treatment. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J., 308, 81-106.
84. CAPRIE steering committee (1996). A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet, 348, 1329-1339.
85. DCCT Research Group (1993). The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N. Engl. J. Med., 329, 977-986.
86. UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853.
87. UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865.
88. Smith, U. (1995). Smoking elicits the insulin resistance syndrome: new aspects of the harmful effects of smoking. J. Intern. Med., 237, 435-437.
89. Eliasson, B., Attvall, S., Taskinen, M.-R. and Smith, U. (1994). The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler. Thromb., 14, 1946-1950.